This back test is a fairly decent representation of my portfolio of Biotech stocks I traded last year. Despite the thin volatility in the IBB and S&P 500, a select few small cap biotech companies had tremendous returns due to PDUFA's and FDA reviews of drug candidates. My strategy is technically incredibly risky, but I think that with proper analysis the risk becomes minute. Best of all, this strategy works with Large- cap stocks as well. The model isn't entirely accurate, however, because my strategy is based on trades and not year long investments, making returns slightly higher than represented here.
Need help?
Contact support.
Company
Learn & Support
Notices
Follow Us
The material on this website is provided for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation or endorsement for any security or strategy, nor does it constitute an offer to provide investment advisory services by Quantopian.
In addition, the material offers no opinion with respect to the suitability of any security or specific investment. No information contained herein should be regarded as a suggestion to engage in or refrain from any investment-related course of action as none of Quantopian nor any of its affiliates is undertaking to provide investment advice, act as an adviser to any plan or entity subject to the Employee Retirement Income Security Act of 1974, as amended, individual retirement account or individual retirement annuity, or give advice in a fiduciary capacity with respect to the materials presented herein. If you are an individual retirement or other investor, contact your financial advisor or other fiduciary unrelated to Quantopian about whether any given investment idea, strategy, product or service described herein may be appropriate for your circumstances. All investments involve risk, including loss of principal. Quantopian makes no guarantees as to the accuracy or completeness of the views expressed in the website. The views are subject to change, and may have become unreliable for various reasons, including changes in market conditions or economic circumstances.